|Acquired by||Takeda Pharmaceutical|
|Series B, 6/07 |
|Series B, 7/09 |
Novartis Venture Funds
US Venture Partners
|Venture Round, 10/11 ||$4M|
Intellikine works in the discovery and development of novel, small molecule therapies targeting the PI3K/Akt/mTOR pathway.
Intellikine is committed to building an exceptional team and a powerful discovery platform that rapidly generates small molecule kinase inhibitor drug candidates that will become the next generation of medical breakthroughs.